SIGLEC1 and neoplasm: CD169+ LNMs further correlated with decreased odds of tumor size above 20 mm (OR = 0.42, p = 0.041) and increased odds of surviving beyond 5 years (OR = 2.20, p = 0.045), while CD169 in PTs (CD169+ TAMs) correlated with high Ki67 levels (OR = 2.33, p = 0.021) (Table 2).